Roughly 6 to 12 percent of US women of reproductive age — on the order of 5 to 6 million people, though estimates vary with the diagnostic criteria used — have PCOS, also known as polycystic ovary syndrome. Despite the name, PCOS is not really about cysts on the ovaries. It is a complex endocrine and metabolic syndrome characterized by irregular menstrual cycles, elevated androgens, and often insulin resistance. Many people with PCOS don’t have visible cysts at all, and many people with multiple ovarian follicles don’t have PCOS. This guide is general information, not medical advice — diagnosis and treatment are individualized decisions you make with a qualified clinician.
The condition is the most common cause of ovulatory infertility in women, accounts for an estimated 70 to 80 percent of anovulatory infertility, and can raise the risk of type 2 diabetes, metabolic syndrome, and endometrial cancer if left unmanaged, according to the NIDDK. This guide explains the diagnostic criteria, the role of insulin resistance, and what treatment looks like depending on whether the priority is acne, fertility, weight, or long-term metabolic health. PCOS is a manageable condition, not a personal failing; the framing here is meant to be practical and non-stigmatizing.
What PCOS Actually Is
PCOS is a heterogeneous syndrome diagnosed clinically by the Rotterdam criteria: at least two of (1) irregular or absent ovulation, (2) clinical or biochemical hyperandrogenism, and (3) polycystic ovarian morphology on ultrasound. Crucially, it is a diagnosis of exclusion — other causes of similar symptoms must be ruled out first, including thyroid disease, hyperprolactinemia, non-classic congenital adrenal hyperplasia, and Cushing’s syndrome. The American College of Obstetricians and Gynecologists (ACOG) and the 2023 international PCOS guideline both endorse the Rotterdam framework for adults while cautioning that it should never rest on a single incidental finding.
The polycystic appearance on ultrasound is defined by a high follicle count per ovary or increased ovarian volume; the exact follicle-number threshold has been revised upward as ultrasound resolution improved, so clinicians rely on current criteria rather than older cutoffs. These are not true cysts but immature follicles arrested in development. The pathophysiology centers on disordered LH and FSH signaling, ovarian androgen overproduction, and insulin resistance, which amplifies androgen production and lowers sex hormone binding globulin. For broader context on metabolic and endocrine conditions, see our guide to chronic conditions.
PCOS phenotypes
Because the Rotterdam criteria allow several combinations, PCOS is often described in four phenotypes (A through D) depending on which features are present. Phenotypes that include hyperandrogenism tend to carry higher metabolic risk, while the “non-hyperandrogenic” phenotype is generally milder metabolically. Understanding your phenotype helps explain why two people with the same label can need very different care.
Symptoms
Menstrual irregularity is the most common presentation — cycles longer than 35 days or fewer than about 8 cycles per year, including amenorrhea. Hyperandrogenism produces hirsutism (excess hair on the face, chest, or abdomen), acne (often along the jawline and chin), and androgenic alopecia (hair thinning at the crown). Many people with PCOS are overweight or have obesity, often with the visceral fat pattern that drives metabolic risk, but a substantial minority have a normal body weight (“lean PCOS”) and still have the hormonal and metabolic features.
Other features include acanthosis nigricans (velvety dark patches in skin folds, a marker of insulin resistance), fatigue, mood symptoms, sleep-disordered breathing, and infertility. Metabolic findings include impaired glucose tolerance in roughly 30 to 40 percent and overt type 2 diabetes in around 10 percent of people with PCOS by age 40, though prevalence figures vary by population and study.
Long-term, PCOS raises the risk of endometrial hyperplasia and cancer (from chronic estrogen unopposed by progesterone when cycles are absent), cardiovascular risk factors, non-alcoholic fatty liver disease (NAFLD, now often called MASLD), and obstructive sleep apnea. Mental health is significantly affected — rates of depression, anxiety, and disordered eating are meaningfully higher than in age-matched people without PCOS, which is why the 2023 international guideline recommends routine screening for mood symptoms as part of standard care.
Diagnosis
Workup confirms the Rotterdam criteria and rules out mimics. Blood tests typically include total and free testosterone, DHEAS, 17-hydroxyprogesterone (to help exclude congenital adrenal hyperplasia), TSH, prolactin, fasting glucose and insulin, hemoglobin A1c, and a lipid panel; an oral glucose tolerance test is often preferred for assessing glucose metabolism. Pelvic ultrasound is often deferred in adolescents because polycystic-appearing ovaries are common and normal in the years after menarche.
The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS — developed with input from ASRM, ESHRE, and dozens of other organizations and summarized in part by the Endocrine Society — refined diagnostic thresholds and endorsed anti-Müllerian hormone (AMH) as a reasonable alternative to ultrasound for assessing ovarian morphology in adults (but not adolescents). It also explicitly recommends against making the diagnosis purely from a single ultrasound finding, and it stresses diagnosing adolescents cautiously. Guidance continues to evolve, so verify current criteria with your clinician.
Treatment by Priority
PCOS treatment is symptom-driven, individualized, and prescriber-directed. Different people need different things, and the same person’s priorities change over time. There is no cure; the goal is to control symptoms and reduce long-term risk. Nothing below is a personal treatment plan — dosing and drug choice are decisions for you and your clinician.
Menstrual regulation and androgen control
Combined hormonal contraceptives are generally first-line for cycle regulation, hirsutism, and acne when pregnancy is not desired; many regimens lower androgens over about 3 to 6 months. Spironolactone is an anti-androgen commonly added for hirsutism and acne, and because it can affect a developing fetus it is paired with reliable contraception. Topical treatments and cosmetic hair-reduction methods (laser, electrolysis) are options for hirsutism. Which medication fits depends on your other risk factors and preferences — a conversation for your OB/GYN or endocrinologist.
Insulin resistance and metabolic health
Metformin remains a cornerstone for many patients. It improves insulin sensitivity, modestly reduces androgen levels, and can support weight management and cycle regularity. GLP-1 receptor agonists (such as semaglutide and liraglutide) and the dual GIP/GLP-1 agonist tirzepatide are increasingly used off-label for PCOS-related obesity and insulin resistance, with substantial average weight loss in weight-management trials. Important caveats: these agents are not FDA-approved specifically for PCOS, must be stopped before conception, and are prescribed and monitored by a clinician — they are not a do-it-yourself option.
Fertility
Letrozole is now generally first-line for ovulation induction in PCOS, having largely replaced clomiphene after the PPCOS II trial showed higher live-birth rates with letrozole; ASRM and the 2023 international guideline both support letrozole as a preferred oral agent. Metformin is sometimes added, and gonadotropins or IVF follow if oral therapy does not succeed. Modest weight loss (roughly 5 to 10 percent of body weight) restores ovulation in many people independent of medication. Fertility care should be directed by an OB/GYN or a reproductive endocrinologist, who will tailor the approach to your history.
Diet and Lifestyle
Lifestyle modification is foundational and recommended for everyone with PCOS regardless of weight. The 2023 international guideline recommends any sustainable, balanced eating pattern rather than promoting one specific “PCOS diet.” Mediterranean-style and lower-glycemic-load patterns have some of the most supportive evidence for improving insulin resistance and androgen levels, but adherence and enjoyment matter more than any single plan. Sustained weight loss of about 5 to 10 percent, where appropriate, reliably improves cycle regularity, fertility, and metabolic markers for many people.
Physical activity of any kind helps; resistance training appears to improve insulin sensitivity in PCOS alongside aerobic exercise. Sleep is often overlooked — obstructive sleep apnea is more common in PCOS than in the general population and worsens insulin resistance independently, so many clinicians screen symptomatic patients. Because weight and body image are sensitive topics, current guidelines emphasize compassionate, weight-inclusive counseling and screening for disordered eating rather than weight-focused pressure.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe pelvic pain (possible ovarian torsion or a hemorrhagic cyst), heavy uterine bleeding with lightheadedness, severe shortness of breath or chest pain (possible blood clot, a risk that can be higher on combined hormonal contraceptives), or signs of very high blood sugar such as rapid breathing, confusion, and severe thirst.
Long-Term Surveillance
PCOS requires ongoing monitoring because its risks extend well beyond the reproductive years. Clinicians commonly recheck glucose status and lipids periodically (often every 1 to 3 years, sooner with added risk factors), monitor blood pressure and weight, screen for depression and anxiety, and assess the endometrium in anyone with prolonged amenorrhea or abnormal uterine bleeding. When contraception is not used, cyclic or continuous progestin is sometimes prescribed to protect the endometrium — a decision individualized by a clinician rather than self-managed.
Cardiovascular risk in PCOS is elevated at the level of risk factors, though the full lifetime impact is still being characterized. According to the Cleveland Clinic, current guidance emphasizes managing metabolic risk factors starting in young adulthood rather than waiting for cardiovascular events.
When to See a Doctor
Cycles longer than 35 days or fewer than about 8 per year, persistent acne or hirsutism, unexplained weight changes with signs of insulin resistance, or difficulty conceiving for more than 6 to 12 months all warrant gynecologic or endocrinologic evaluation. PCOS is often diagnosed and managed in primary care, but complex management — fertility, refractory metabolic disease, or an ambiguous diagnosis — usually benefits from specialist input. If cost is a concern, our healthcare costs guide covers ways to plan for labs, imaging, and specialist visits.
Frequently Asked Questions
Can I have PCOS without cysts on my ovaries?
Yes. PCOS can be diagnosed by the Rotterdam criteria with just two of three features. Many people have irregular cycles plus hyperandrogenism without polycystic-appearing ovaries on ultrasound. The name is genuinely misleading — the “cysts” are immature follicles, not true cysts.
Will PCOS go away after menopause?
Cycle problems resolve with menopause by definition, and hyperandrogenism often improves though it may persist. The metabolic risks — diabetes, cardiovascular disease, and fatty liver disease — continue and still need attention. PCOS is best thought of as a lifelong metabolic condition, not only a reproductive one.
Is PCOS reversible with weight loss?
Weight loss, where appropriate, markedly improves PCOS features for many people who have overweight or obesity; cycle regularity, fertility, and metabolic markers often improve substantially with around 10 percent weight loss. “Lean” PCOS is a different phenotype where weight loss is less relevant, and treatment focuses on insulin sensitivity and androgen control. There is no “cure,” but symptoms are often well controlled.
Are GLP-1 medications safe for PCOS?
GLP-1 receptor agonists are not FDA-approved specifically for PCOS but are widely used off-label, particularly for obesity in PCOS, under a prescriber’s supervision. They are not recommended in pregnancy and should be stopped before conception. Because some people with PCOS begin ovulating during weight loss, contraception planning matters if pregnancy is not desired. Discuss risks, benefits, and monitoring with your clinician.
Does PCOS increase the risk of endometrial cancer?
Prolonged absence of ovulation means the uterine lining can be exposed to estrogen without the balancing effect of progesterone, which over time can raise the risk of endometrial hyperplasia and cancer. This is why clinicians pay attention to cycle frequency and abnormal bleeding, and why cyclic progestin or hormonal contraception is sometimes recommended to protect the endometrium.
The Bottom Line
PCOS is best understood as a metabolic and endocrine syndrome that happens to affect the ovaries — not the other way around. Treatment matches your current priority: contraception and androgen control, fertility, weight and metabolic health, or long-term risk reduction, and it should always be individualized with a clinician. The long-term goal is preventing diabetes, cardiovascular disease, and endometrial cancer, which means PCOS doesn’t end at the last fertility cycle. It needs lifelong, compassionate attention — and it is a manageable condition, not something to be ashamed of.
Medical disclaimer: This article is for general informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. PCOS is diagnosed and managed individually with a qualified clinician after other conditions are excluded. Medications named here — including hormonal contraceptives, anti-androgens, metformin, letrozole, and off-label GLP-1 drugs — are prescriber-directed and are not do-it-yourself treatments. Guidelines, thresholds, and drug approvals change, so verify current details with your clinician. Seek emergency care for sudden severe pelvic pain, heavy bleeding with faintness, or chest pain and shortness of breath.
Sources
- NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) — PCOS overview, prevalence, and associated risks
- MedlinePlus — Polycystic ovary syndrome (definition, symptoms, and treatment overview)
- American College of Obstetricians and Gynecologists (ACOG) — PCOS FAQ and practice guidance
- American Society for Reproductive Medicine (ASRM) — ovulation induction and fertility care in PCOS (letrozole as a preferred agent)
- 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS (endorsed by ASRM, ESHRE, and others) — diagnosis, AMH, mental-health screening, and management
- Endocrine Society — clinical practice guidance on PCOS diagnosis and treatment
- Cleveland Clinic — polycystic ovary syndrome (cardiometabolic risk management)